Pacemaker Device & Lead Design Optimization Patent Landscape
Filing activity in pacemaker device and lead design optimization is concentrated among a small number of specialized firms and academic medical centers, with Shiratronics Inc holding a commanding lead. Annual filing volume peaked in 2019 and has since eased materially, signaling a field in decline rather than active expansion.
Shiratronics leads a highly concentrated, specialist-driven field
Shiratronics Inc sits at the top of the applicant ranking with 34 patent records, followed by Pacesetter Inc with 16 and Intermedics Inc with 14. The top five filers together account for 57% of the hundred largest filers’ combined total, indicating a highly concentrated competitive structure dominated by niche device companies rather than large diversified medtech groups.
A clear tier gap separates Shiratronics from the rest of the field. The next four ranked applicants — Pacesetter Inc, Intermedics Inc, Medtronic Inc, and Syntilla Medical LLC — each hold between 9 and 16 patent records, forming a mid-tier cluster with no single challenger approaching Shiratronics’ position. Below rank five, counts drop sharply to single digits.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Shiratronics Inc | 34 | |
| 2 | Pacesetter Inc | 16 | |
| 3 | Intermedics Inc | 14 | |
| 4 | Medtronic Inc | 13 | |
| 5 | Syntilla Medical LLC | 9 | |
| 6 | SmartImplantSystems Inc | 8 | |
| 7 | University of Southern California | 7 | |
| 8 | Children’s Hospital of Los Angeles | 7 | |
| 9 | Telectronics | 5 | |
| 10 | NEURO & CARDIAC TECHNOLOGIES LLC | 4 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Cardia Access Inc | 4 | |
| 12 | EPQuant LLC | 3 | |
| 13 | Boston Scientific Neuromodulation Corporation | 3 | |
| 14 | Northwestern University | 3 | |
| 15 | Paul A. Lovoi | 2 | |
| 16 | Robert G. Walsh | 2 | |
| 17 | G. Frank O. Tyers | 2 | |
| 18 | Birinder R. Boveja | 2 | |
| 19 | Howard C. Hughes | 2 | |
| 20 | James H. Donachy | 2 |
Shiratronics’ position implies that it has been the primary driver of recent conceptual advancement in this sub-field. However, the presence of academic medical centers — University of Southern California and Children’s Hospital of Los Angeles — in the top ten suggests that some innovation pipeline originates outside purely commercial R&D.
Patents filed in the most recent 18–24 months are subject to publication lag and are likely under-represented in this dataset; very recent activity should not be read as definitive. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Activity peaked in 2019; electrotherapy dominates the technology mix
The filing trend chart shows how annual activity has evolved from 2017 to the present, while the technology composition chart reveals the IPC class distribution across the corpus.
Annual filing trend
Annual filings reached a peak of 16 records in 2019 before declining sharply. Counts for 2023 onward reflect publication lag and should be treated as provisional minima rather than confirmed activity levels. The overall picture is one of a field that surged briefly around 2019 and has since contracted.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61N (Electrotherapy and radiation therapy) is overwhelmingly dominant in the IPC composition, with adjacent classes — A61B (Diagnosis and surgery) and A61M (Devices for body fluids) — each contributing a much smaller share. Niche branches such as A61L (Sterilising and disinfecting), H01B (Cables, conductors and insulators), and G01R (Electric and magnetic measurement) each account for a minimal portion, highlighting how narrowly the corpus is technically scoped.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Apparatus and method for treatment of neurological…
System and method for neuromodulation therapy of neurological and neuropsychiatric disorders comprises an implantable lead and pulse generator system for providing the appropriate electrical stimulation to a cranial nerve such as the vagus nerve. The implantable pulse generator having prepackaged/predetermined programs stored in the memory of the pulse… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Apparatus and method for treatment of neurological… | 423 |
| 2 | Method and system for providing therapy for autism… | 330 |
| 3 | Epicardial lead for minimally invasive implantation | 325 |
| 4 | Transvenously implantable lead | 264 |
| 5 | Medical electrical lead and introducer system for … | 250 |
| 6 | Method and system for providing therapy for bulimi… | 230 |
| 7 | Method and system for altering regional cerebral b… | 227 |
| 8 | Method and system for providing therapy for bulimi… | 166 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the competitive structure means for R&D investment decisions
The combination of high concentration, post-peak filing volume, and sparse adjacent branches shapes where new entrants or incumbents can most efficiently deploy resources.
Field is in decline, with volume easing sharply from its 2019 peak
The lifecycle stage is classified as Decline, driven by annual filings easing back from the 2019 peak of 16 records. A recent-window growth figure of –71% confirms the contraction is material. For R&D planners, this signals that foundational device and lead architecture claims are largely staked; differentiation through adjacent technical angles is likely more defensible than head-on prosecution in the core A61N space.
Decline stageOne dominant filer; mid-tier cluster provides limited competitive pressure on Shiratronics
The top five filers account for 57% of the hundred largest filers’ combined total, and Shiratronics alone holds 34 patent records — more than double the next-ranked applicant. This degree of concentration means that freedom-to-operate analyses should prioritize Shiratronics’ portfolio first. The mid-tier (Pacesetter, Intermedics, Medtronic, Syntilla) presents secondary blocking risk particularly in electrotherapy-specific claim structures.
High concentrationAcademic–industry co-filing active between Children’s Hospital of Los Angeles and USC
The most active co-filing pair is Children’s Hospital of Los Angeles and the University of Southern California, with 7 joint filings. Syntilla Medical LLC and Shiratronics Inc form the second notable pair with 5 joint filings. These collaborations suggest that pediatric cardiology and neurostimulation-adjacent pacemaker research are active institutional focus areas. A new entrant seeking academic partnerships may find both USC and Children’s Hospital of Los Angeles as accessible co-development nodes.
Academic co-filingUnited States dominates; EPO and PCT routes indicate selective international pursuit
The United States leads jurisdiction coverage, followed by Europe (EPO) and WIPO (PCT). Australia and Canada appear as secondary markets. The concentration in US filings reflects both the domestic origin of leading applicants and the commercial primacy of the US medical device market. Competitors seeking to block or design around key patents should focus freedom-to-operate searches on US records first, with EPO as a secondary priority.
US-centricGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Children’s Hospital of Los Angeles | University of Southern California | 7 |
| Syntilla Medical LLC | Shiratronics Inc | 5 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Shiratronics and Pacesetter lead, with diverging recent trajectories
The top two applicants both focus on the core A61N electrotherapy class, but their recent filing momentum differs sharply, with Shiratronics classified as a new entrant building its position while Pacesetter’s activity has declined steeply.
Shiratronics Inc
Shiratronics holds 34 patent records — the largest position in the corpus — concentrated entirely in A61N 1 (Electrotherapy) with 7 records in recent filings. Its momentum is classified as a new entrant, indicating it has built this leading position relatively recently from a small prior base. This trajectory suggests an aggressive, focused prosecution strategy in core pacemaker electrotherapy architecture. It also co-files with Syntilla Medical LLC (5 joint filings), extending its collaborative reach.
patent records: 34Pacesetter Inc
Pacesetter Inc holds 16 patent records and is the most technically diversified of the major applicants, spanning A61N 1 (Electrotherapy, 11 records), A61M 25 (Devices for body fluids, 9 records), and A61B 17 (Diagnosis and surgery, 5 records). However, its recent filing trend shows a sharp contraction of –90% versus the prior period, signaling a significant pullback in active prosecution. Its multi-class coverage nonetheless represents legacy blocking positions across lead delivery and catheter-adjacent technologies.
patent records: 16| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Pacesetter Inc | 1 | ▼ -90% |
| Children’s Hospital of Los Angeles | 1 | ▲ new entrant |
| University of Southern California | 1 | ▲ new entrant |
| Shiratronics Inc | 2 | ▲ new entrant |
Under-served technical branches adjacent to the dominant electrotherapy core
Several IPC classes appear sparsely in the corpus relative to the dominant A61N class. These are observations of relative patent density — entry viability depends on technical fit and commercial context.
H01B · Cables, conductors and insulators
H01B accounts for only 3 patent records, representing 2% of the IPC composition. For pacemaker lead design specifically, conductor material science — including novel alloys, polymer insulation, and multi-lumen cable architectures — is a technically meaningful dimension that is sparsely covered. An entrant with materials or wire-manufacturing expertise could find lower prior-art density here. A realistic entry path would involve filing around specific conductor cross-sections, insulation chemistries, or fatigue-resistance geometries that are not claimed by the dominant A61N estate.
Search this in Eureka →G01R · Electric and magnetic measurement
G01R appears only once in the corpus, making it the sparsest observed branch. Sensing and diagnostic functions embedded within pacemaker leads — such as impedance monitoring, far-field signal rejection, or MRI compatibility testing — fall under this class and are plausible areas of technical development as leads become smarter. The near-absence of filings here is an observation of low density, not a confirmed gap; prior art may exist in adjacent datasets. A realistic entry path for a firm with signal-processing or measurement capability would be lead-integrated diagnostic claims co-classified with A61N.
Search this in Eureka →Frequently asked questions
The corpus covers 48 patent families. Applicant rankings within the corpus are reported at the patent-record level, which can differ from family counts because a single family may generate records across multiple jurisdictions.
Shiratronics Inc leads with 34 patent records, more than double the next-ranked applicant (Pacesetter Inc at 16). Shiratronics’ technology focus is concentrated in A61N 1 (Electrotherapy), and its filing momentum is classified as a new entrant, indicating it has built this position relatively recently.
The field is classified as Decline. Annual filing volume peaked at 16 records in 2019 and has eased sharply since, with a recent-window growth figure of -71%. This indicates that foundational claim positions are largely established and active prosecution has contracted significantly.
The United States leads jurisdiction coverage, followed by Europe (EPO) and WIPO (PCT). Australia and Canada are secondary markets. Freedom-to-operate searches should prioritize US records, with EPO as a secondary priority.
Yes. The most active co-filing pair is Children’s Hospital of Los Angeles and the University of Southern California, with 7 joint filings. Syntilla Medical LLC and Shiratronics Inc form the second most active pair with 5 joint filings, reflecting an industry–academic structure in the innovation pipeline.
H01B (Cables, conductors and insulators) accounts for 3 patent records (2% of the IPC composition) and G01R (Electric and magnetic measurement) has only 1 record (1%). Both are adjacent to the dominant A61N class and may represent areas of lower prior-art density for entrants with relevant materials or sensing capabilities.
Built on Patsnap Open Platform
This report’s underlying patent dataset — filings, assignees, technology clusters — is open for developers via MCP and REST API. Free to start, 10,000 credits, no credit card required.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.